Navigation Links
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
Date:4/24/2013

not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2013 (the "Form 10-K") and other periodic reports filed with the SEC, including but not limited to the following: (i) the risks related to the uncertain, lengthy and expensive clinical development process for the company's product candidates, including having no unexpected safety, toxicology, clinical or other issues and having no unexpected clinical trial results such as unexpected new clinical data and unexpected additional analysis of existing clinical data; (ii) risks related to the regulatory process for the company's product candidates, including the possibility that the results of the new 52-week Phase 3 clinical trial (ASCEND) having an FVC endpoint may not be satisfactory to the FDA for InterMune to receive regulatory approval for pirfenidone in the United States; (iii) risks related to unexpected regulatory actions or delays or government regulation generally; (iv) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue; (v) government, industry and general public pricing pressures; (vi) risks related to our ability to successfully launch and commercialize Esbriet in Europe and Canada, including successfully establishing a commercial operation in Europe and Canada and receiving favorable governmental pricing and reimbursement approvals in the various European countries and securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans in Canada; and (vii) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections.  The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other fa
'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
8. InterMune To Release First Quarter Financial Results On April 24
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Texas (PRWEB) November 21, 2014 ... is a professional and in-depth research report on ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:11/21/2014)... , Nov. 20, 2014 /CNW/ - Aequus Pharmaceuticals ... announce that it has closed a brokered private ... for approximately C$3.7 million.  Cormark Securities Inc. and ... the Brokered Offering for a syndicate of agents ... Financial Corp. (collectively the "Agents"). Concurrently with the ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... month periods ended September 30, 2014.  Biorem,s complete 2014 third quarter ... ). Financial Summary:Three-months ended September 30, , ... share data) , 2014 , 2013 ... , 5,281 , 6,715 , ...
(Date:11/18/2014)... FL (PRWEB) November 17, 2014 ... point-of-care diagnostic tests – today announces its third ... and Prevention’s (CDC) Get Smart About Antibiotics Week ... Week is a national campaign designed to highlight ... health departments, and non-profit and for-profit partners to ...
Breaking Biology Technology:International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... July 24 Abaxis, Inc.,(Nasdaq: ABAX ), a medical ... for the first,fiscal quarter ended June 30, 2008., ... 7% over last year,s comparable quarter. -- Total sales ... units or 19% over last year,s ...
... hospital physicians, pulmonary and critical care clinicians, ... about overuse of antibiotics, DURHAM, N.C., July ... conferences of the American Thoracic Society and,Society of ... care physicians, and researchers are unanimous in their ...
... 24 Glasses embedded with a telescope,promise to ... to drive and do,other activities requiring sharper distance ... of these innovative glasses,over earlier devices in an ... Biomedical Optics, mailed to subscribers in print form ...
Cached Biology Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009 8U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 2U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 3Telescope Embedded in Spectacle Lens Promises to Make Driving Easier for Visually Impaired 2Telescope Embedded in Spectacle Lens Promises to Make Driving Easier for Visually Impaired 3
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/7/2014)... by Dr. Debra Auguste, associate professor, biomedical engineering, ... City College of New York, have identified a ... one of the most aggressive forms of breast ... a high mortality rate owing to aggressive proliferation ... options. However, Professor Auguste,s team, discovered the overexpression ...
(Date:11/6/2014)... deaths occur because of metastasis, yet progress in ... slow. , "It,s been particularly challenging to design ... research fellow in systems biology at Harvard Medical ... until after they,ve already metastasized." , Gujral and ... should help researchers better understand how metastasis begins. ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Migration negation 2Migration negation 3
... has been shown to improve the neurological function ... University of Traditional Chinese Medicine, China showed that ... cells positive for 5-bromodeoxyuridine, a cell proliferation-related marker, ... growth-associated protein 43, a marker of synaptic plasticity ...
... potential is the direct current potential difference between the ... Its initial amplitude is a significant indicator of the ... well as injury current, can be modulated by direct ... electrical field are hard to define. Dr. Guanghao Zhang ...
... 6, 2013 /PRNewswire-iReach/ -- IdentiSys Inc., North America,s ... card issuance, emergency response, and access control security systems, ... world,s leader in Customer and Patient Experience Management systems. ... from Qmatic to the marketplace and will be the ...
Cached Biology News:IdentiSys brings Qmatic Q-Guide Queuing Systems to the North American market 2IdentiSys brings Qmatic Q-Guide Queuing Systems to the North American market 3
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Functionally tested for consistent G-banding of chromosomes....
... Silver Staining Kit is uniquely formulated ... with minimal protein modification for optimal ... problems associated with traditional silver stains ... because the reagents used do not ...
...
Biology Products: